NDAC Chair
This article was originally published in The Tan Sheet
Executive Summary
An "Appointed Chair" for the Nonprescription Drugs Advisory Committee will run meetings until a final selection is made for a permanent chair, according to FDA. Previous NDAC Chairman Alastair Wood, MD, concluded his term May 31. Wood will begin his role as a managing director at the New York-based private equity firm Symphony Capital in September (1"The Tan Sheet" May 8, 2006, p. 3) A permanent Chair normally is selected from the committee...
You may also be interested in...
NDAC’s Wood Departs FDA Committee; Joins Private Investment Firm
Nonprescription Drugs Advisory Committee Chairman Alastair Wood, MD, will depart NDAC in May and take a position at New York-based private equity firm Symphony Capital, the company announced May 1
Sumitomo To Reprioritize Pipeline After Ulotaront’s Phase III Fail
Sumitomo Pharma is to focus more on late-stage candidates in oncology and cell/gene therapy while passing on full global rights for ulotaront and SEP-380135 to Otsuka.
Lilly, BMS, Microsoft On GenAI’s Machine-First Approach Success, Cell Therapy Use, Regulation
As Eli Lilly chief information and digital officer Rau speaks of generative AI models training humans on drug discovery, Bristol Myers Squibb CDTO Meyers of wearables aiding cell therapy and Microsoft Research India MD Rajamani of interoperability no longer being a huge challenge, a discussion at the BioAsia summit highlights a fundamental shift in R&D approaches.